Serving Overlooked PatientsSM
We develop dose-form innovations of established medicines for patients who have unmet needs.
Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients.
We supply a large number of products to treat a wide range of medical conditions. These include cardiovascular, central nervous system, endocrine, gastro-intestinal, anti-infective and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications, BOXED WARNING and Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
NEW PRODUCT ANNOUNCEMENT
Click for Full Prescribing Information, including Indications, BOXED WARNING and Safety Information.
News & Events
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
MYHIBBIN™ (mycophenolate mofetil oral suspension)
MEDIA ALERT: WOBURN, Mass. May 6, 2024 – Azurity Pharmaceuticals, a pharmaceutical company focused on developing innovative dose forms and formulations of products to serve the needs of overlooked patients, announced today that the U.S. Food and Drug Administration (FDA) has approved Myhibbin™…
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing
MEDIA ALERT: – January 24, 2024 – Woburn, Massachusetts, Azurity Pharmaceuticals, Inc. is voluntarily recalling one (1) lot (F230169A) of
Zenzedi® CII (dextroamphetamine sulfate tablets, USP) 30 mg to the consumer level. The product is being recalled due to a report…
